Samil PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Samil PharmaceuticalLtd's earnings have been declining at an average annual rate of -4.6%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 13.8% per year.
Key information
-4.6%
Earnings growth rate
-4.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 13.8% |
| Return on equity | -0.7% |
| Net Margin | -0.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Some Samil Pharmaceutical Co.,Ltd (KRX:000520) Shareholders Look For Exit As Shares Take 27% Pounding
Nov 18
Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking
Sep 13We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt
Sep 11Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking
Jul 29Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?
May 24There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump
Mar 30Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality
Mar 21Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden
Apr 01Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment
Mar 11Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?
Feb 15
Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?
Jan 20Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend
Dec 24Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment
Dec 09What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?
Nov 18Revenue & Expenses Breakdown
How Samil PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 212,424 | -1,174 | 67,229 | 5,828 |
| 30 Jun 24 | 210,733 | -1,155 | 64,532 | 5,913 |
| 31 Mar 24 | 204,905 | -786 | 61,461 | 5,870 |
| 31 Dec 23 | 196,346 | 1,664 | 59,962 | 5,601 |
| 30 Sep 23 | 189,293 | 2,600 | 59,638 | 5,249 |
| 30 Jun 23 | 183,060 | 1,336 | 59,752 | 4,342 |
| 31 Mar 23 | 179,566 | 343 | 58,907 | 3,553 |
| 31 Dec 22 | 179,676 | -28 | 58,519 | 2,907 |
| 30 Sep 22 | 170,510 | -4,989 | 55,364 | 2,359 |
| 30 Jun 22 | 158,910 | -4,740 | 51,226 | 2,617 |
| 31 Mar 22 | 147,877 | -5,619 | 48,047 | 2,948 |
| 31 Dec 21 | 134,247 | -5,347 | 43,763 | 2,971 |
| 30 Sep 21 | 129,974 | -2,761 | 41,634 | 3,007 |
| 30 Jun 21 | 127,287 | -1,327 | 40,709 | 3,007 |
| 31 Mar 21 | 122,793 | 132 | 38,960 | 2,593 |
| 31 Dec 20 | 122,999 | 1,341 | 37,989 | 3,007 |
| 30 Sep 20 | 123,114 | 940 | 36,510 | 3,185 |
| 30 Jun 20 | 122,308 | 729 | 37,087 | 2,847 |
| 31 Mar 20 | 123,102 | 1,429 | 37,461 | 3,183 |
| 31 Dec 19 | 121,107 | 786 | 37,453 | 3,060 |
| 30 Sep 19 | 114,364 | -1,251 | 37,792 | 3,060 |
| 30 Jun 19 | 107,856 | -3,368 | 37,017 | 2,969 |
| 31 Mar 19 | 102,805 | -6,461 | 37,498 | 2,619 |
| 31 Dec 18 | 94,600 | -8,563 | 37,373 | 2,182 |
| 30 Sep 18 | 96,882 | -5,165 | 37,580 | 2,026 |
| 30 Jun 18 | 94,916 | -4,605 | 36,925 | 2,087 |
| 31 Mar 18 | 92,286 | -2,797 | 36,168 | 1,987 |
| 31 Dec 17 | 92,038 | -1,267 | 36,734 | 1,961 |
| 30 Sep 17 | 90,658 | -1,434 | 35,792 | 1,938 |
| 30 Jun 17 | 92,118 | 898 | 35,357 | 1,605 |
| 31 Mar 17 | 94,685 | 948 | 35,882 | 1,447 |
| 31 Dec 16 | 96,758 | 887 | 35,667 | 1,254 |
| 30 Sep 16 | 94,010 | 306 | 35,309 | 1,047 |
| 30 Jun 16 | 92,625 | 140 | 34,909 | 1,136 |
| 31 Mar 16 | 88,656 | 553 | 33,503 | 1,121 |
| 31 Dec 15 | 88,136 | 588 | 33,688 | 1,119 |
| 30 Sep 15 | 85,795 | -2,986 | 35,250 | 1,457 |
| 30 Jun 15 | 85,439 | -6,170 | 36,903 | 1,831 |
| 31 Mar 15 | 85,849 | -10,179 | 39,225 | 2,477 |
| 31 Dec 14 | 85,461 | -11,190 | 39,011 | 2,790 |
| 30 Sep 14 | 87,683 | 1,148 | 37,998 | 2,841 |
| 30 Jun 14 | 87,545 | 3,601 | 37,061 | 2,126 |
| 31 Mar 14 | 89,207 | 7,191 | 34,562 | 2,182 |
| 31 Dec 13 | 89,229 | 7,930 | 34,631 | 2,046 |
Quality Earnings: A000520 is currently unprofitable.
Growing Profit Margin: A000520 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A000520 is unprofitable, and losses have increased over the past 5 years at a rate of 4.6% per year.
Accelerating Growth: Unable to compare A000520's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A000520 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: A000520 has a negative Return on Equity (-0.67%), as it is currently unprofitable.